These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 25513996)

  • 1. Comparison of Toxicity and Treatment Outcomes in HIV-positive Versus HIV-negative Patients With Squamous Cell Carcinoma of the Anal Canal.
    White EC; Khodayari B; Erickson KT; Lien WW; Hwang-Graziano J; Rao AR
    Am J Clin Oncol; 2017 Aug; 40(4):386-392. PubMed ID: 25513996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era.
    Grew D; Bitterman D; Leichman CG; Leichman L; Sanfilippo N; Moore HG; Du K
    Dis Colon Rectum; 2015 Dec; 58(12):1130-6. PubMed ID: 26544809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
    Fraunholz IB; Haberl A; Klauke S; Gute P; Rödel CM
    Dis Colon Rectum; 2014 Apr; 57(4):423-31. PubMed ID: 24608297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy.
    Oehler-Jänne C; Huguet F; Provencher S; Seifert B; Negretti L; Riener MO; Bonet M; Allal AS; Ciernik IF
    J Clin Oncol; 2008 May; 26(15):2550-7. PubMed ID: 18427149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-Free Survival and Time to Complete Response After Definitive Chemoradiotherapy for Squamous-Cell Carcinoma of the Anus According to HIV Infection.
    Camandaroba MPG; Iseas S; Oliveira C; Taboada RG; Xerfan MP; Mauro CC; Silva VS; Barros M; de Jesus VHF; Felismino T; Aguiar S; Gobo ML; Mello CA; Riechelmann RP
    Clin Colorectal Cancer; 2020 Sep; 19(3):e129-e136. PubMed ID: 32389596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.
    Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH
    Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
    Hauerstock D; Ennis RD; Grossbard M; Evans A
    Clin Colorectal Cancer; 2010 Oct; 9(4):238-42. PubMed ID: 20920996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.
    White EC; Goldman K; Aleshin A; Lien WW; Rao AR
    Radiother Oncol; 2015 Nov; 117(2):240-5. PubMed ID: 26347494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are there HIV-specific Differences for Anal Cancer Patients Treated with Standard Chemoradiotherapy in the Era of Combined Antiretroviral Therapy?
    Martin D; Balermpas P; Fokas E; Rödel C; Yildirim M
    Clin Oncol (R Coll Radiol); 2017 Apr; 29(4):248-255. PubMed ID: 28049602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy.
    Wexler A; Berson AM; Goldstone SE; Waltzman R; Penzer J; Maisonet OG; McDermott B; Rescigno J
    Dis Colon Rectum; 2008 Jan; 51(1):73-81. PubMed ID: 18066626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients With Squamous Cell Anal Cancer.
    Leiker AJ; Wang CJ; Sanford NN; Aguilera TA; Karri S; Beg MS; Kazmi SA; Olson C; Matthews JA; Abdelnaby A; Meyer JJ; Folkert MR
    Am J Clin Oncol; 2020 Oct; 43(10):701-708. PubMed ID: 32694298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of anal cancer patients at the Ottawa hospital.
    Abunassar M; Reinders J; Jonker DJ; Asmis T
    Eur J Surg Oncol; 2015 May; 41(5):653-8. PubMed ID: 25776438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.
    Wo JY; Plastaras JP; Metz JM; Jiang W; Yeap BY; Drapek LC; Adams J; Baglini C; Ryan DP; Murphy JE; Parikh AR; Allen JN; Clark JW; Blaszkowsky LS; DeLaney TF; Ben-Josef E; Hong TS
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):90-95. PubMed ID: 31128146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and Predictive Clinicopathologic Factors of Squamous Anal Canal Cancer in HIV-Positive and HIV-Negative Patients: Does HAART Influence Outcomes?
    Pappou EP; Magruder JT; Fu T; Hicks CW; Herman JM; Fang S; Wick EC; Safar B; Gearhart SL; Efron JE
    World J Surg; 2018 Mar; 42(3):876-883. PubMed ID: 28948325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
    Seo Y; Kinsella MT; Reynolds HL; Chipman G; Remick SC; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):143-9. PubMed ID: 19203845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy.
    Blazy A; Hennequin C; Gornet JM; Furco A; Gérard L; Lémann M; Maylin C
    Dis Colon Rectum; 2005 Jun; 48(6):1176-81. PubMed ID: 15906137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy.
    Stadler RF; Gregorcyk SG; Euhus DM; Place RJ; Huber PJ; Simmang CL
    Dis Colon Rectum; 2004 Aug; 47(8):1305-9. PubMed ID: 15484343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients.
    Abramowitz L; Mathieu N; Roudot-Thoraval F; Lemarchand N; Bauer P; Hennequin C; Mitry E; Romelaer C; Aparicio T; Sobhani I
    Aliment Pharmacol Ther; 2009 Aug; 30(4):414-21. PubMed ID: 19392867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
    Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P
    Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.